Summary David Li , Co-Founder and CEO of Meliora Therapeutics , sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how the platform technology to uncover the true ...

Investors entering the landscape of venture capital are often bombarded with acronyms for terms that can seem foreign. While a general understanding of the concept that the term represents can be understood by context, knowing the complete meaning of these terms can provide powerful insight into better understanding the return profile of an investment and help make better informed investments. In this paper, we hope to elucidate some commonly used acronyms and the concepts behind them in order to make the world of VC more accessible to anyone approaching it.

We are excited to bring you a new episode of "The One Away Show" with Bryan Wish which featured our Founder and CEO, Neil Littman! Here he discussed investing in causes one believes in, being motivated by impacting more people's lives, financial opportunities in the healthcare industry, as well as ...

We're thrilled to share that Bioverge hosted an Ask Me Anything (AMA) session on July 20, 2023, where we dove into the depths of biotech and healthcare venture capital. During the AMA session, our CEO Neil Littman addressed ...

One little girl opened my eyes to the awe-inspiring innovative possibilities emerging in healthcare and biotechnology. Every day we’re seeing profound breakthroughs in biological research that are rapidly transforming our understanding of disease and the human body. Equally exciting are advancements in technology in computing and beyond. In biotech, the ...

Presenting the Venture Capital 101 whitepaper highlighting the background and basics of VC for potential investors.

Modulo Bio has built a neuroimmune platform based on the integration of an iterative machine learning model and a clinically relevant cellular model which guides the discovery of novel disease-targeted neuroimmune therapeutics.

Anat Burkovitz, CEO of TrojanBio, sits down with Neil to discuss its AI-drive antibodies platform, how it enlists the viral immune system in the fight against cancer, and why she thinks the technology will broaden the population of patients who will benefit from immunotherapies.

On the latest episode of The Bioverge Podcast, Amit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil Littman to discuss the lack of innovation in psychiatric medicines, how Alto has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.